With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially
Digital health company Cumulus Neuroscience has teamed up with two UK universities to develop its at-home electroencephalogram (EEG) headset as an early warning system for
The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa
Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg
After much deliberation, the FDA has granted accelerated approval for Biogen’s tofersen for an ultra-rare form of the neurodegenerative disease amyotrophic lateral scleros